This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA)
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Top Performing Stocks of the Best ETF of 1H2018
by Sweta Killa
Inside the top performing stocks of the top ETF of the first half of 2018.
Achieve Life Sciences' Shares Rise on Positive Clinical Data
by Zacks Equity Research
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
Top Ranked Momentum Stocks to Buy for June 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 19th:
Play the Best Sector of Summer With These ETFs & Stocks
by Sanghamitra Saha
Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.
Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon
by Zacks Equity Research
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
Bayer's Generic Competition, Pipeline Setback Issues Remain
by Zacks Equity Research
Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
by Zacks Equity Research
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
by Zacks Equity Research
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
by Zacks Equity Research
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
by Zacks Equity Research
Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
by Zacks Equity Research
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
by Zacks Equity Research
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
by Zacks Equity Research
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
by Zacks Equity Research
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
by Zacks Equity Research
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
by Zacks Equity Research
Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
Will Agency Growth Aid Booking Holdings (BKNG) Q1 Earnings?
by Zacks Equity Research
Booking Holdings' (BKNG) Q1 earnings are likely to reflect growth in international markets.
ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.